15 November 2012 - Therapeutics and diagnostics company Nymox Pharmaceutical Corporation (NasdaqCM:NYMX) revealed on Wednesday a net loss of USD1.24m, or USD0.04 per share, for the third quarter of 2012.

This marks a growth when compared to the net loss of USD1.614m or USD0.05 per share, for the quarter, which ended 30 September 2011.

A net loss of USD4.81m, or USD0.15 per share, was announced for the nine months ended 30 September 2012, which is an improvement when compared to USD7.99m, or USD0.24 per share, for the nine months ended 30 September 2011.

The company said that the decrease in net losses is attributable primarily to lower stock-based compensation charges in 2012 compared to 2011.

Sales revenues was USD319,837 for the nine months ended 30 September 2012, down when compared to sales revenues of USD373,009 for the same period in 2011.